TCGA-E9-A1N6-01A-11R-A144-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 23
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- CHOLESTEROL_HOMEOSTASIS+0.500
- MTORC1_SIGNALING+0.450
- G2M_CHECKPOINT+0.440
- E2F_TARGETS+0.430
- ANGIOGENESIS+0.420
- MITOTIC_SPINDLE+0.350
- UV_RESPONSE_UP+0.330
- TGF_BETA_SIGNALING+0.320
- MYC_TARGETS_V1+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.220
- IL6_JAK_STAT3_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.170
- INTERFERON_GAMMA_RESPONSE-0.140
- INTERFERON_ALPHA_RESPONSE-0.050
- INFLAMMATORY_RESPONSE-0.030
- KRAS_SIGNALING_UP-0.030
- HEME_METABOLISM-0.020
- SPERMATOGENESIS-0.020
- MYOGENESIS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-68-7756-01A-11R-2125-07 | — | cohortSQ1 | 0.852 |
| 2 | SRR17866829 | — | — | 0.850 |
| 3 | SRR934967 | — | — | 0.844 |
| 4 | SRR8943009 | — | — | 0.843 |
| 5 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.841 |
| 6 | MNG252 | — | — | 0.840 |
| 7 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.837 |
| 8 | TCGA-FD-A6TH-01A-11R-A32O-07 | — | — | 0.832 |
| 9 | TCGA-55-6975-01A-11R-1949-07 | — | cohortA4 | 0.828 |
| 10 | DRR168536 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.500 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |